CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention

Borse Mrudula S.; Dong Olivia M.; Polasek Melissa J.; Farley Joel F.; Stouffer George A.; Lee Craig R.

首页> 外文期刊>Pharmacogenomics >CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention

【24h】

CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention

机译：CYP2C19引导抗血小板治疗：经皮冠状动脉干预后30天和1年成果的成本效益分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: Determine whether using CYP2C19 genotype to optimize antiplatelet therapy selection is cost effective over the initial 30 days and 1-year following percutaneous coronary intervention. Materials & methods: A cost-effectiveness analysis compared 30-day and 1-year outcomes and cost across three treatment strategies (universal clopidogrel, universal prasugrel, genotype-guided) in a hypothetical cohort. Results: Base-case scenario results at 30 days indicated that the incremental cost per major cardiovascular or bleeding event avoided for genotype-guided treatment was US$8525 and US$42,198 compared with universal clopidogrel and prasugrel, respectively. Probabilistic sensitivity analysis demonstrated that genotype-guided treatment was cost effective over 30 days and 1 year in 62 and 70% of simulations, respectively. Conclusion: Implementing a CYP2C19 genotype-guided approach to antiplatelet therapy could have a positive economic impact by preventing readmissions following percutaneous coronary intervention.

机译：目的：确定在经皮冠状动脉介入术后最初30天和1年内，使用CYP2C19基因型优化抗血小板治疗选择是否具有成本效益。材料与方法：成本-效果分析比较了一个假设队列中三种治疗策略（通用氯吡格雷、通用普拉格雷、基因型指导）的30天和1年结果和成本。结果：30天的基本病例情景结果表明，基因型指导治疗避免的每一重大心血管或出血事件的增量成本分别为8525美元和42198美元，与通用氯吡格雷和普拉格雷相比。概率敏感性分析表明，在62%和70%的模拟中，基因型指导治疗分别在30天和1年内具有成本效益。结论：实施CYP2C19基因型指导的抗血小板治疗方法可以通过预防经皮冠状动脉介入术后再入院产生积极的经济影响。

著录项

来源
《Pharmacogenomics》 |2017年第12期|共12页
作者
Borse Mrudula S.; Dong Olivia M.; Polasek Melissa J.; Farley Joel F.; Stouffer George A.; Lee Craig R.;
展开▼
作者单位

Univ North Carolina Chapel Hill UNC Eshelman Sch Pharm Div Pharmaceut Outcomes &

Policy Chapel;

Univ North Carolina Chapel Hill UNC Eshelman Sch Pharm Div Pharmacotherapy &

Expt Therapeut;

Univ North Carolina Chapel Hill UNC Eshelman Sch Pharm Div Pharmacotherapy &

Expt Therapeut;

Univ North Carolina Chapel Hill UNC Eshelman Sch Pharm Div Pharmaceut Outcomes &

Policy Chapel;

Univ North Carolina Chapel Hill UNC McAllister Heart Inst Chapel Hill NC 27599 USA;

Univ North Carolina Chapel Hill UNC Eshelman Sch Pharm Div Pharmacotherapy &

Expt Therapeut;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
clopidogrel; cost-effectiveness; CYP2C19; genotype; pharmacogenomics; prasugrel; readmission;

机译：Clopidogrel;成本效益;CYP2C19;基因型;药物蛋白质;普拉布雷;再次入住;

相似文献

外文文献
中文文献
专利

1. Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis [J] . Pei Zhu, Run-Lin Gag, Bo Xu, 中华医学杂志（英文版） . 2017,第024期
2. Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis [J] . Jayswal Saheb K, DENG Bing-qing, HU Qing-song, 中华医学杂志（英文版） . 2013,第013期
3. Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: a meta-analysis [J] . ZHANG Yong, TANG Hai-qin, LI Jin, 中华医学杂志（英文版） . 2013,第009期
4. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention [J] . Borse Mrudula S., Dong Olivia M., Polasek Melissa J., Pharmacogenomics . 2017,第12期

机译：CYP2C19引导抗血小板治疗：经皮冠状动脉干预后30天和1年成果的成本效益分析
5. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention [J] . Galper Benjamin Z., Reynolds Matthew R., Garg Pallav, Coronary artery disease . 2019,第3期

机译：短持续时间双抗血小板治疗的成本效果分析与较新的药物洗脱支架平台与较长持续时间双抗血小板治疗，第二代药用支架在选修的经皮冠状动脉介入中
6. Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study [J] . JingLi, Yi Li, Miaohan Qiu, Catheterization and cardiovascular interventions: Official journal of the Society for Cardiac Angiography & Interventions . 2020,第S1期

机译：双抗血小板治疗持续时间对糖尿病患者急性冠状动脉综合征患者1年临床结果的影响：现实世界选择性研究的见解
7. Impact of Renal Insufficiency on 30-Day Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention [C] . Sakai K., Tosaka A., Soga Y., World Congress on Heart Disease. . 2013

机译：肾功能不全对患有初步经皮冠状动脉介入治疗的ST段抬高心肌梗死30天后的影响
8. The Association between Unfractionated Heparin and Bivalirudin Used during Percutaneous Coronary Intervention for Stable Angina and Acute Coronary Syndromes and the In-Hospital and Mortality Outcomes Observed across All Body Mass Index Groups [D] . Chen, Christine. 2021

机译：在所有体重指数群体中观察到稳定冠状动脉干预期间使用经皮冠状动脉介入和急性冠状动脉综合征的冠状动脉介入和医院和死亡率结果之间的联合肝素和Bivalirudin之间的关联
9. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond One Year after Percutaneous Coronary Intervention: An Analysis from the Randomized Dual Antiplatelet Therapy Study [O] . Robert W. Yeh, Eric A. Secemsky, Dean J. Kereiakes, -1

机译：经皮冠状动脉介入治疗一年后双重抗血小板治疗益处和危害的预测规则的开发和验证：来自随机双重抗血小板治疗研究的分析
10. CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention [O] . Alexis K. Williams, Melissa D. Klein, Jesse Martin, 2019

机译：CYP2C19基因型引导抗血小板治疗和经皮冠状动脉干预后的30天后
11. Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease. Executive Summary. Effective Health Care Program Research Report No. 9 [R] . 2007

机译：经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗冠心病的疗效比较。执行摘要。有效的医疗保健计划研究报告第9号

CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention

摘要

著录项

相似文献

相关主题

期刊订阅